Mark Sheridan is a Partner with leading business advisory firm Mazars in Brisbane. He has a Bachelor of Commerce (Honours) and is a Fellow of Chartered Accountants Australia and New Zealand. He is also a Fellow of the Institute of Managers and Leaders and a member of the Australian Institute of Company Directors.
He was appointed a Director of the Prevent Blindness Foundation in 2003 and Chairman of the Foundation from April 2011.
Prof. Mark Radford has been Executive Director and Chief Executive Officer for the Queensland Eye Institute since March 2010.
Mark completed his first undergraduate degree at Flinders University of South Australia in 1978. After being awarded a Japanese Government (Mombusho) Fellowship, Mark completed his Doctor of Medicine at Nagasaki University School of Medicine in 1992. During this period he also completed a PhD at Flinders University (1989).
Mark started his working career as a research academic (lecturer and later Associate Professor) at Hokkaido University in Japan. Between 1993 and 2003, Mark served as a consultant to a number of government and private organisations worldwide, before returning to Hokkaido University to become Professor within the Department of Behavioural Science.
In 2006, Mark returned to Australia to become CEO and Managing Director of Symbiosis Group Limited – a life science investment, management and commercialisation company based in Brisbane, Australia.
Mark has extensive experience in medical research, teaching and management. He has published extensively in the area of medicine, culture & behaviour, leadership and decision-making.
Mark is a member of a number of professional associations. He is Fellow of both the Australian Institute of Company Directors (AICD) and Australian Institute of Management (AIM).
Jemma Elder is a Managing Director with Publicis Australia, an entity of the Publicis Groupe one of the world’s largest media and communications agency networks. Her remit spans the management of businesses in commercial partnership with Publicis including Personalised Plates Queensland (Department of Transport and Main Roads), KiwiPlates (New Zealand Transport Agency). Jemma brings extensive business, sales and marketing experience having previously worked in senior positions with ASX listed companies.
Jemma holds a Bachelor of Business and Grad Certificate Applied Finance. She is a member of the AICD and sits on Advisory Committees that foster entrepreneurial learning & enterprise development.
John is a Special Counsel with Shand Taylor Lawyers which he joined as a Partner in 2007. Previously he was the Principal of Lowes & Co, a predominantly property focused law firm which he ran for 11 years. Prior to this he was a Partner for eight years with an international law firm. John holds a Bachelor of Arts and a Bachelor of Law.
With over 39 years as a practising solicitor, John concentrated on all aspects of property, small business law and private client advisory. He has also acted for a broad range of health professionals and specialist medical groups. John gained Specialist Accreditation in Property Law from the Queensland Law Society in 2002 and served for ten years as a member of their Specialist Accreditation Board.
Mario is a strategic advisor and consultant with more than 30 years’ experience in managing and growing commercial operations in the life sciences industry. He is a government-appointed Member of the Queensland University of Technology (QUT) Council, and associated committees, including as Chair of the IHBI External Engagement Committee. He is also the Chair of Griffith University’s Clinical Trials Advisory Committee and a Member of the Queensland Government’s Biofutures Industry Advisory Group.
Mario’s Non-Executive Director roles include Elo Life Systems Australia Pty Ltd, Alpine Immune Sciences Australia Pty Ltd, Integral Scopes Pty Ltd, and Chair of Suncare Community Services Ltd. Previous roles include executive positions at Sullivan Nicolaides Pathology and Mayne Group as well as serving as CEO of Life Sciences Queensland Ltd. and Queensland Clinical Trials Network Inc.